Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Arvinas, Inc. ARVN
$22.78
-$0.12 (-0.52%)
На 18:01, 12 мая 2023
+262.16%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1224425312.00000000
-
week52high
58.58
-
week52low
22.10
-
Revenue
131400000
-
P/E TTM
-5
-
Beta
1.75534900
-
EPS
-4.90000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 12:30
Описание компании
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Oppenheimer | Outperform | Outperform | 08 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 05 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 05 авг 2022 г. |
| Credit Suisse | Outperform | Outperform | 05 авг 2022 г. |
| Jefferies | Hold | 21 июн 2022 г. | |
| Barclays | Overweight | 09 сент 2022 г. | |
| Morgan Stanley | Equal-Weight | Equal-Weight | 11 ноя 2022 г. |
| SVB Leerink | Outperform | Outperform | 23 ноя 2022 г. |
| Piper Sandler | Overweight | Overweight | 23 ноя 2022 г. |
| Barclays | Overweight | Overweight | 23 ноя 2022 г. |
| SVB Leerink | Outperform | Outperform | 22 ноя 2022 г. |
| Wells Fargo | Equal-Weight | Overweight | 03 янв 2023 г. |
| Citigroup | Buy | Buy | 05 дек 2022 г. |
| Truist Securities | Buy | Buy | 17 янв 2023 г. |
| Guggenheim | Neutral | Buy | 12 янв 2023 г. |
| Cantor Fitzgerald | Overweight | 31 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Cunningham Everett | A | 30095 | 30095 | 15 дек 2022 г. |
| YOUNG JOHN D | A | 24572 | 24572 | 18 авг 2022 г. |
| Peck Ronald | D | 4010 | 4010 | 12 авг 2022 г. |
| Peck Ronald | D | 8154 | 1258 | 12 авг 2022 г. |
| Peck Ronald | A | 9412 | 4010 | 12 авг 2022 г. |
| Norwalk Leslie V | A | 10192 | 10192 | 16 июн 2022 г. |
| Morrison Briggs | A | 10192 | 10192 | 16 июн 2022 г. |
| Margus Bradley Albert | A | 10192 | 10192 | 16 июн 2022 г. |
| Bain Linda | A | 10192 | 10192 | 16 июн 2022 г. |
| Smaldone Alsup Laurie | A | 10192 | 10192 | 16 июн 2022 г. |
Новостная лента
Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research
05 мая 2023 г. в 09:54
Arvinas, Inc. (ARVN) came out with a quarterly loss of $1.54 per share versus the Zacks Consensus Estimate of a loss of $1.46. This compares to loss of $1.20 per share a year ago.
Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference
GlobeNewsWire
03 мая 2023 г. в 07:00
NEW HAVEN, Conn., May 03, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Sean Cassidy, Chief Financial Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development, will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on Tuesday, May 9 at 6:40 p.m. ET/3:40 p.m. PT in Las Vegas.
Arvinas to Present at Stifel Targeted Oncology Day
GlobeNewsWire
21 апр 2023 г. в 16:00
NEW HAVEN, Conn., April 21, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside at the Stifel Targeted Oncology Day on Wednesday, April 26 at 11:30 a.m. ET.
Arvinas, Inc. (ARVN) Surges 7.6%: Is This an Indication of Further Gains?
Zacks Investment Research
14 апр 2023 г. в 04:36
Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Arvinas to Participate in Upcoming Investor Conferences
GlobeNewsWire
27 февр 2023 г. в 16:00
NEW HAVEN, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences: